Scilex Holding (SCLXW) Income from Continuing Operations (2020 - 2026)

Scilex Holding (SCLXW) recorded quarterly Income from Continuing Operations of 45650000.0 in Q1 2026, up 0.99% quarter-over-quarter from 46105000.0 in Q4 2025, and down 75.04% on a YoY basis from 182880491.55 in Q1 2025.

Scilex Holding (SCLXW) Income from Continuing Operations (2020 - 2026) Analysis & Trends

Scilex Holding's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 45650000.0 for Q1 2026.

  • In Q1 2026, Income from Continuing Operations fell 75.04% year-over-year to 45650000.0; the TTM figure through Mar 2026 stood at 393623000.0 (down 428.28% YoY), while the FY2025 annual figure was 374053000.0, down 413.76% from the prior year.
  • Income from Continuing Operations was 45650000.0 for Q1 2026 at Scilex Holding, up from 46105000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 21501000.0 in Q3 2022 to a low of 257820000.0 in Q3 2025.
  • Historically, Income from Continuing Operations has averaged 37070882.35 across 5 years, with a median of 26080000.0 in 2025.
  • Biggest YoY gain for Income from Continuing Operations was 7736.6% in 2022; the steepest drop was 10688.09% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 17884000.0 in 2022, then declined by 19.66% to 21400000.0 in 2023, then jumped by 69.81% to 6460000.0 in 2024, then plunged by 613.7% to 46105000.0 in 2025, then increased by 0.99% to 45650000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 45650000.0 (Q1 2026), 46105000.0 (Q4 2025), and 257820000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Scilex Holding - - 4.15 Mn -45.65 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -45.65 Mn
Dec 31, 2025 -46.11 Mn
Sep 30, 2025 -257.82 Mn
Jun 30, 2025 -44.05 Mn
Mar 31, 2025 -26.08 Mn
Dec 31, 2024 -6.46 Mn
Sep 30, 2024 -4.39 Mn
Jun 30, 2024 -37.58 Mn
Mar 31, 2024 -24.38 Mn
Dec 31, 2023 -21.40 Mn
Sep 30, 2023 -35.53 Mn
Jun 30, 2023 -26.65 Mn
Mar 31, 2023 -30.75 Mn
Dec 31, 2022 -17.88 Mn
Sep 30, 2022 21.50 Mn
Jun 30, 2022 -17.84 Mn
Mar 31, 2022 -9.14 Mn
Dec 31, 2021 -35.26 Mn
Sep 30, 2021 -281,552.00
Jun 30, 2021 -165,349.00